Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.

Oncotarget · 2014 · PMC4294371 · PMID 25402820

Europe PMC DOI

hedged sentence

0.0002

closest p · 0.0× alpha

0.0002

boldest claim

The sentences

failed to reach statistical significanceP=0.0002actually significant

While CBL0137 and gemcitabine monotherapy had only a modest effect on PANC-1 orthotopic tumor growth, which failed to reach statistical significance (39% and 20% growth inhibition, respectively), the combination of the two agents caused a substantial decrease in PANC-1 tumor growth (78% growth inhibition, P=0.0002; Fig. 2A ).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.